BioPharmSignal logoBioPharmSignal

Biotech News

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Protara Therapeutics (TARA)Protara TherapeuticsEarnings

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H

Open original release

Related news

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

View all latest news

Protara Therapeutics

Protara Therapeutics is a biotechnology company focused on rare disease and oncology programs, including metabolic and lymphatic disease. Its story centers on high-unmet-need conditions and a narrow pipeline.

Recent company news

TARAProtara Therapeutics2026-05-20 12:00 EST

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-04-27 20:05 EST

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

Stock data

Close
4.04 USD
Market cap
243.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States